Conflicts of interest I.D.W.S. and J.F. are co-founders of Lumicure, which manufactures and produces the organic light-emitting diodes. A.McN. is employed by Lumicure.
An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer
Article first published online: 19 MAR 2009
© 2009 The Authors. Journal Compilation © 2009 British Association of Dermatologists
British Journal of Dermatology
Volume 161, Issue 1, pages 170–173, July 2009
How to Cite
Attili, S.K., Lesar, A., McNeill, A., Camacho-Lopez, M., Moseley, H., Ibbotson, S., Samuel, I.D.W. and Ferguson, J. (2009), An open pilot study of ambulatory photodynamic therapy using a wearable low-irradiance organic light-emitting diode light source in the treatment of nonmelanoma skin cancer. British Journal of Dermatology, 161: 170–173. doi: 10.1111/j.1365-2133.2009.09096.x
- Issue published online: 22 JUN 2009
- Article first published online: 19 MAR 2009
- Accepted for publication 2 December 2008
- organic light-emitting diode;
- photodynamic therapy;
- skin cancer
Background Photodynamic therapy (PDT) is a popular treatment for nonmelanoma skin cancer with clearance rates of between 70% and 100%. Although reported to have a superior cosmetic outcome, the inconvenience of hospital visits and discomfort during therapy are considered drawbacks.
Objectives To present an open pilot study of a low-irradiance, potentially disposable, lightweight, organic light-emitting diode (OLED), which is an area-emitting light source (2 cm diameter), suitable for ambulatory PDT.
Methods Twelve patients with Bowen’s disease (eight) and superficial basal cell carcinoma (four) < 2 cm in diameter were recruited into the study following histological confirmation of the diagnosis. Two treatments (45–60 J cm−2 red light, 550–750 nm, peak 620 nm, irradiance 5 mW cm−2) were administered 1 month apart following application of aminolaevulinic acid for 4 h.
Results At the 12-month follow-up, seven of the 12 patients remained clear, with four of the nonresponders demonstrating peripheral margin failure. Patients were scored for pain during and immediately after treatment using the numerical rating scale (NRS; 1–10). All 12 subjects scored pain as < 2 using the NRS (median score 1). In contrast, a similar cohort of 50 consecutive patients from our routine PDT clinic (Aktilite® inorganic LED source; 75 J cm−2, irradiance 80 mW cm−2) scored a median of 6 on the NRS.
Conclusions Pain and inconvenience are practical barriers to the use of conventional PDT. This pilot study suggests that OLED-PDT is less painful than conventional PDT with the added advantage of being lightweight, and therefore has the potential for more convenient ‘home PDT’. These results need to be validated in larger studies.